Antibody-enhanced COVID-19 vaccination

Bidragets beskrivning

A major challenge in COVID-19 vaccinations is to induce robust and good-quality protective immunity, especially in older persons. We will use a clinically approved therapeutic antibodies to overcome these limitations in experimental models. By co-injecting small quantities of immunomodulatory antibodies with the with a vaccine antigen we will revive the COVID-19 vaccine responses in aged immune system, and re-direct the anti-vaccine immune response to the most beneficial protecting direction. Our conceptually new way of using accepted therapeutic antibodies as COVID-19 vaccine adjuvants has the potential to generate more effective vaccine responses with less adverse effects, substantial vaccine-sparing and the protection of older individuals.
Visa mer

Startår

2020

Slutår

2022

Beviljade finansiering

Marko Salmi Orcid -palvelun logo
531 859 €

Finansiär

Finlands Akademi

Typ av finansiering

Akademiprojekt med särskild inriktning

Övriga uppgifter

Finansieringsbeslutets nummer

336422

Vetenskapsområden

Biomedicinska vetenskaper

Forskningsområden

Biolääketieteet

Temaområden

Lisätalousarvio III 2020

Identifierade teman

covid, pandemic, vaccines